Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-303 first-in-human study in advanced solid tumors
jRCT2031230705Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of DF4101 and budigalimab in Nonhematologic neoplasms (2 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of participants with adverse events. Started May 2024; status: active, not recruiting.
02
Drugs
DF4101budigalimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230705.